

The Association of Glycated Hemoglobin and Lipid Profile with Peripheral Artery Disease in Metabolic Syndrome Patients from Northwestern Algeria

Imane Bouragba*¹  , Mustapha Diaf²  , Sarra Souiah³  , Melih Asmaa³  , Mellali Attouya³  

¹Department of Biology, Laboratoire de Microbiologie Moléculaire, Protéomique et Santé, Faculty of Natural and Life Sciences, Djillali LIABES University, Sidi-Bel-Abbes, Algeria.

²Department of Biology, Laboratoire de Nutrition, Pathologie, Agrobiotechnologie et Santé, Faculty of Natural and Life Sciences, Djillali LIABES University, Sidi-Bel-Abbes, Algeria

³Department of Biology, Faculty of Natural and Life Sciences, Djillali LIABES University, Sidi-Bel-Abbes, Algeria.

*Corresponding Author.

Received 10/09/2023, Revised 12/12/2023, Accepted 14/12/2023, Published Online First 20/02/2024



© 2022 The Author(s). Published by College of Science for Women, University of Baghdad.

This is an Open Access article distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glycated hemoglobin (HbA1c) was incorporated as an indicator of dysglycemia, as opposed to fasting glycaemia, for the purpose of classifying patients based on their vascular incidents. This choice was made due to HbA1c's robust correlation with vascular factors like pulse wave velocity, intima media thickness, and the albumin/creatinine ratio (ACR). However, the relationship between HbA1c and lipid profile in developing artery disease remain uncertain. We set out to investigate the association of HbA1c and lipid profile with peripheral artery diseases (PAD) in patients with metabolic syndrome (MetS) in north-western Algeria. Our cross sectional study was carried out during six months. The BMI was calculated as weight(kg)/height²(m²). Ankle-brachial index (ABI)<0.9 and angiography was used to diagnosed PAD and MetS was defined according NCEP-ATPIII criteria. Statistical test, involving correlations and linear regression, were employed to establish the link between HbA1c, fasting glycemia, lipid profile, and the occurrence of PAD in individuals with MetS. In a sample of 300 MetS patients, 53% were male. Positive associations were observed between HbA1c, fasting blood glucose (FBG) ($r=0.753$, $p<0.001$), and triglycerides (TG) ($r=0.288$, $p<0.001$), with a negative correlation seen with high-density lipoprotein (HDL) ($r= -0.356$, $p<0.001$). HbA1c exhibited no significant correlation with total cholesterol (TC) and low-density lipoprotein (LDL). Lipid ratios (LDL/HDL, TC/HDL, TG/HDL) were positively linked to HbA1c ($r=0.232$, $r=0.332$ and $r=0.43$, respectively). Linear regression affirmed these findings. HbA1c displayed positive ties with FBG and TG, while negatively correlated with HDL, showing independence from LDL and TC. Notably, all three lipid ratios showed significant associations with HbA1c

Keywords: Glycated hemoglobin, lipid profile, lipid ratio, metabolic syndrome, peripheral artery disease.

Introduction

The metabolic syndrome (MetS) is a pathological condition that affects a large proportion of the worldwide population, characterized by the coexistence of different metabolic factors

simultaneously, such as arterial hypertension, diabetes and atherogenic dyslipidemia¹. Dyslipidemia is defined as an imbalance in serum lipid levels, whether of primary or secondary

origin. It is a chronic metabolic disorder characterized by hypertriglyceridemia, total hypercholesterolemia, high LDL and low HDL levels². This coexistence leads to various complications, such as kidney diseases, hepatic steatosis, obstructive sleep apnea, cancer, polycystic ovary syndrome, chronic inflammation, sympathetic activation and hyperuricemia, and above all atherothrombotic cardiovascular disease (CVD)^{3,4}.

Atherothrombosis, in turn, results from thrombus formation induced by atherosclerotic plaque ulceration and platelet activation. Atherosclerosis is due to the accumulation of modified lipids (oxidized LDL) in the walls of large and medium-caliber arteries⁵. This causes a number of different complications, such as peripheral arterial disease (PAD) that affects the arteries that pump blood to the legs and feet. In addition to narrowing and blockages, artery walls lose their elasticity, preventing them from dilating to increase blood flow. Inadequate circulation can cause intermittent claudication and muscle weakness, skin lesions (tissue ulceration and necrosis) and even amputations, all of which affect quality of life⁶.

Materials and Methods

Data collection

This cross-sectional study was conducted over six-months (from January to June 2023), in the diabetology-endocrinology department of the University Hospital of the *Wilaya* of Sidi-Bel-Abbes, located in the northwestern Algeria. Adult diabetics suffering from MetS with or without PAD were included in this study in order to investigate the association of HbA1c and lipid profile with PAD in MetS.

Patients' medical records were analyzed for biochemical parameters such as C-Reactive protein (CRP), FBG, HbA1c, Total Cholesterol (TC), Triglycerides (TG), High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) as well as for medical history. A face-to-face interview was carried out to obtain additional information about the patient (age of the patient, age of pathologies such as diabetes, hypertension and dyslipidemia). Anthropometric parameters (body weight, height and waist circumference) were measured in the standing position. The BMI was calculated as $BMI (kg/m^2) =$

Glycated hemoglobin (HbA1c) is regularly tested in diabetics to monitor blood glycemia. It is recognized as the gold standard for glycemic control. A level of below 7% is considered the target for optimal glycemic control^{7,8}. Glycated hemoglobin has emerged as a biomarker of cardiovascular and metabolic risk. Previous studies have demonstrated a strong association between HbA1c and MetS components⁹ suggesting that an elevated HbA1c may predict dysmetabolism¹⁰.

The International Diabetes Federation (IDF) has included HbA1c as a marker of dysglycemia rather than fasting blood glucose (FBG) to categorize patients according to their vascular attacks, based on their cardiovascular and metabolic risk linked to atherosclerosis¹¹, as the HbA1c is strongly associated with vascular parameters such as pulse wave velocity, intima media thickness and Albumin-to-Creatinine ratio (ACR)¹²⁻¹⁴. Several studies have reported a significant relationship between lipid profile and HbA1c¹⁵, while others reported no considerable relationship¹⁶. The aim of this study is to investigate the association of glycated hemoglobin and lipid profile with PAD in MetS patients from Northwestern Algeria.

$weight(kg)/height^2 (m^2)$. Blood pressure was measured using a sphygmomanometer. Hypertension was defined as a systolic blood pressure of 140 mmHg and diastolic blood pressure of about 90 mmHg or more. MetS was defined according to NCEP ATP III criteria³. PAD was diagnosed by an ankle-brachial index (ABI) <0.9 and confirmed by angiography.

Study population

We enrolled adult diabetic individuals seeking consultation at the diabetology-endocrinology department of the University Hospital of Sidi Bel Abbes, located in north-western Algeria, during the period from January to June 2023. This recruitment included those with Metabolic Syndrome (MetS) in association with Peripheral Arterial Disease (PAD) (n = 91), as well as those without this association (n = 209).

Inclusion Criteria

- Adult men and women with diabetes and Metabolic Syndrome;
- Participants willing to participate in the interview;
- Individuals not afflicted by cancer, severe cardiovascular disease (CVD), chronic kidney disease, acute infections, autoimmune diseases, infectious diseases, HIV, or HCV.

Exclusion Criteria

- Participants who declined to take part in the interview;
- Individuals without Metabolic Syndrome, those with cancer, severe CVD, chronic kidney diseases, acute infections, autoimmune diseases, infectious diseases, HIV, and HCV;
- Pregnant women.

Results

Three hundred patients with MetS were included in the present study, 53% were males and 91 (30.35%) participants developed PAD. All participants were diabetics (100%), 39.33% were hypertensive, and 35.33% had dyslipidemia. Patients with PAD were significantly ($p < 0.001$) older than those without PAD, with a mean age of 65.28 (± 10.87) and 51.43 (± 16.54) years, respectively. Comparing the two groups of PAD (without PAD and with PAD),

Statistical analysis

Data analysis were processed and performed using the Statistical Package for Social Sciences® software (SPSS, version 20.0) and the Microsoft Excel 2013 program. Results are presented as means \pm standard deviations. Student's independent t -test was used to compare mean values between the two groups of PAD (with PAD and without PAD). Patients are then classified into two groups according to HbA1c levels ($< 7\%$, $\geq 7\%$) based on the American Diabetes Association classification¹⁷. The Pearson correlation coefficient and linear regression test were applied to determine the association between HbA1c, FBG and lipid profile.

Highly significant differences ($p < 0.001$) were demonstrated through Student's t -test regarding, CRP, HDL, TC, TG levels and lipid ratios (LDL/HDL, TC/HDL and TG/HDL). Significant differences were highlighted for waist circumference ($p = 0.013$), LDL ($p = 0.003$), HbA1c ($p = 0.002$) and FBG ($p = 0.002$) levels. CRP, TC, TG, LDL, HbA1c, FBG levels and lipid ratios were higher in the PAD group. In contrast, HDL levels were low (Table 1).

Table 1. Basic characteristics of metabolic syndrome patients with and without peripheral artery diseases.

Parameters	Total (n=300)	Without PAD (n=209)	With PAD (n=91)	<i>p</i>
Male gender; n (%)	159 (53.00)	96 (60.37)	63 (39.62)	$< 0.001^*$
Age (years)	55.63 \pm 16.33	51.43 \pm 16.54	65.28 \pm 10.87	$< 0.001^{\#}$
Diabetes; n (%)	300 (100)	209 (69.66)	91 (30.35)	-
Hypertension; n (%)	118 (39.33)	71 (60.16)	47 (39.83)	0.004*
Dyslipidemia; n (%)	106 (35.33)	15 (14.15)	91 (85.84)	$< 0.001^*$
BMI (kg/m ²)	26.63 \pm 05.89	26.35 \pm 05.38	27.50 \pm 07.20	0.201 [#]
Waist circumference (cm)	99.51 \pm 14.85	97.79 \pm 14.22	104.31 \pm 15.69	0.013 [#]
Systolic pressure (cmHg)	12.37 \pm 2.11	12.30 \pm 2.25	12.53 \pm 1.75	0.391 [#]
Diastolic pressure (cmHg)	7.18 \pm 1.06	7.21 \pm 1.05	7.11 \pm 1.11	0.476 [#]
HbA1c (%)	9.99 \pm 3.25	9.60 \pm 3.38	10.90 \pm 2.74	0.002 [#]
Fasting blood glucose (g/L)	2.75 \pm 1.17	2.59 \pm 1.24	3.10 \pm 0.94	0.002 [#]
CRP (g/L)	53.81 \pm 69.39	37.35 \pm 57.50	78.43 \pm 79.25	$< 0.001^*$
LDLc (g/L)	1.12 \pm 0.53	1.01 \pm 0.42	1.26 \pm 0.61	0.003 [#]
TC (g/L)	1.88 \pm 0.59	1.70 \pm 0.47	2.17 \pm 0.66	$< 0.001^*$
TG (g/L)	1.64 \pm 0.70	1.35 \pm 0.45	2.92 \pm 0.88	$< 0.001^*$
HDLc (g/L)	0.36 \pm 0.08	0.39 \pm 0.09	0.32 \pm 0.05	$< 0.001^*$
LDL/HDL	3.25 \pm 1.80	2.70 \pm 1.63	3.98 \pm 2.04	$< 0.001^*$
TC/LDL	5.49 \pm 2.34	4.43 \pm 1.63	6.90 \pm 2.42	$< 0.001^*$
TG/LDL	6.08 \pm 4.31	3.47 \pm 1.37	9.71 \pm 4.39	$< 0.001^*$

Quantitative variables are given in mean (\pm Standard Deviation); Qualitative variables are given in number (frequency); (#) *p* value for student *t* test; (*) *p* value for Chi-square test; $p \leq 0.05$ was considered as statistically significant. PAD: Peripheral Artery Disease, BMI: Body Mass Index, HbA1c: Glycated hemoglobin, CRP: C-Reactive Protein, LDL: Low Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides, HDL: High Density Lipoprotein.

Comparison of traditional lipid parameters (HDL, LDL, TG and TC) and FBG between patients with and without PAD according to HbA1c levels shows higher levels of FBG, TC, TG and LDL in PAD patients for both classes of HbA1c. However, HDL levels were lower (Fig.1).




Figure 1. Comparison of fasting blood glucose levels and lipid profile between patients with and without PAD according to HbA1c levels.

The three lipid ratios show elevated values in PAD patients in both classes of HbA1c (Fig. 2).




Figure 2. Comparison of lipid ratios between patients with and without PAD according to HbA1c levels.

Pearson correlation of HbA1c with FBG and traditional lipid parameters (HDL, LDL, TC and TG) shows a strong and significant positive relationship between HbA1c and FBG ($r = 0.753, p < 0.001$) and a weak significant positive correlation between HbA1c and TG ($r = 0.288, p < 0.001$). However, a negative correlation was found with HDL ($r = -0.356, p < 0.001$). There was no significant correlation with TC and LDL. Likewise, lipid ratios; LDL/HDL, TC/HDL, TG/HDL were positively correlated with HbA1c ($r = 0.232, r = 0.332$ and $r = 0.43$, respectively) (Table 2).

Table 2. Correlation and linear regression analysis (between HbA1c, fasting blood glucose, and lipid parameters)

Parameters	Correlation Coefficient	P-value [#]	Regression Unstandardized coefficients b	P-value*
FBG (g/L)	0.753	<0.001 [#]	1.951	<0.001*
HDL (g/L)	-0.356	<0.001 [#]	-12.622	<0.001*
LDL (g/L)	0.068	0.405	10.117	0.405
TC (g/L)	0.132	0.066	0.660	0.065
TG (g/L)	0.288	<0.001 [#]	0.860	<0.001*
LDL/HDL	0.232	0.004 [#]	0.366	0.004*
TC/HDL	0.332	<0.001 [#]	0.406	<0.001*
TG/HDL	0.430	<0.001 [#]	0.295	<0.001*

(#) *p* value for **Pearson correlation**; (*) *p* value for **linear regression test**; $p \leq 0.05$ was considered as statistically significant. FBG: Fasting blood glucose, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides, HbA1c: Glycated hemoglobin.

The linear regression revealed that HbA1c levels were positively associated with FBG, TG and lipid ratios ($p < 0.05$), negatively associated with HDL ($p < 0.001$) and independent of other parameters (LDL and TC) (Table 2).

Discussion

Recently, HbA1c has emerged as a biomarker of cardiovascular and metabolic risk. Previous studies have demonstrated a strong association between HbA1c and MetS components, suggesting that an elevated HbA1c may predict dysmetabolism¹⁰.

IDF has included HbA1c as a marker of dysglycemia rather than FBG for the classification of patients according to their vascular attacks, based on their cardiovascular and metabolic risk linked to atherosclerosis¹¹, as the HbA1c is strongly associated with vascular parameters such as pulse wave velocity, intima media thickness and ACR¹²⁻¹⁴. Preliminary findings of the present study showed that 30.35% of MetS patients with a mean age of $55.63 \pm (16.33)$ years developed PAD. In the present study, all patients were diabetics (100%), 39.33% were hypertensive, of which 39.34% with PAD and 35.33% had dyslipidemia, of which 85.84% with PAD.

In the United States, in 2020, 21 million people (18%) aged 65 and over have PAD. Given the ageing of the population, this number is projected to rise to 23.8 million by 2030¹⁸. In two other recent studies, the prevalence of PAD in people aged 65 and over was 13.5% and 27.7%¹⁹. In an Indian study, the prevalence was 36% in diabetics. A higher prevalence (62.3%) was estimated in diabetic patients by Gninkoun et al²⁰. In Algeria, Rachid et al

reported that 16% of patients with coronary artery diseases had PAD²¹. The incidence of PAD in MetS patients was 1.7% (23/1382) versus 0.87% (30/3435) in non-MetS subjects (30/3435)²². Moreover, Petra et al reported that MetS affects 58% of PAD patients²³.

The present PAD patients were significantly older than those without PAD. Several previous studies have reported that the prevalence of PAD in patients with diabetes increases with age^{24, 25}. The PAD group showed higher levels of TG, TC, LDL, HbA1c, FBG and waist circumference than the second group. In agreement with the present study, Mohammed et al reported that age, gender, BMI, systolic and diastolic blood pressure, HbA1c, serum LDL, TG and current or past smoking are potential risk factors presenting significant associations with the incidence of PAD²⁶. In addition, Hafida's statistical analysis demonstrated a significant relationship between obliterative arterial disease of the lower limbs and age, smoking, TC and LDL²⁷. Recent results from the Bypass Angioplasty Revascularisation Investigation in type 2 diabetes (BARI 2D) study revealed that a 1% increase in HbA1c was associated with a 21% increased risk of PAD in type 2 diabetics²⁸. Moussio et al, noted an increase in HbA1c levels in type 2 diabetics with PAD^{29, 30}. Our findings highlighted higher levels of FBG, TC, TG and LDL in the presence of PAD

associated with elevated HbA1c levels. However, HDL levels were lower.

We found a strong and significant positive association between HbA1c and FBG ($r = 0.753$, $p < 0.001$) and a weak and significant positive correlation between HbA1c and TG ($r = 0.288$, $p < 0.001$). However, a negative correlation was found with HDL ($r = -0.356$, $p < 0.001$). There was no significant correlation with TC and LDL, our results concurred with those reported by several previous studies, HbA1c levels rise as lipid profile parameters increase (TC, TG, LDL, and VLDL) and HDL levels decrease³¹⁻³³. Alzahrani et al, found no relationship between HbA1c and lipid profile (TC, LDL and HDLc), with the exception of TG; they suggest that TG may predict CVD and is a risk factor in type 2 diabetes³⁴. In contrast, a minority of studies have revealed a positive relationship between HbA1c and HDL^{8, 35}. The current findings revealed that HbA1c levels were positively associated with FBG and TG ($p < 0.001$), negatively associated with HDL

($p < 0.001$) and independent of other parameters (LDL and TC). Another study reported that HbA1c could be a predictive factor for TG, TC and LDL in contrast FBG and age did not correlate with HbA1c³². In this study, lipid ratios (LDL/HDL, TC/HDL, TG/HDL) had significant associations with HbA1c levels. These outcomes are consistent with those reported by Artha et al the lipid ratio parameter TC-TG-LDL/HDL ratio were significantly higher in the group with poor glycemic control ($p < 0.05$)³⁶. Hussain et al (2017) found that HbA1c was positively and significantly related to LDL/HDL ratio³².

The present study is firstly limited by the cross-sectional design. Secondly, the majority of our participants were treated with antihypertensive drugs, oral antidiabetics, insulin and statins, which could reduce lipid and blood sugar estimations. third, this single-center study conducted on a small sample size precludes generalizability of the findings to a large diverse population.

Conclusion

High levels of TC, TG, LDL, HbA1c and FBG were associated with PAD in MetS patients; HbA1c was positively correlated with FBG and TG, negatively correlated with HDL and independent of LDL and TC. However, all three lipid ratios are significantly associated with HbA1c, suggesting that regular

monitoring of the glycaemic and lipid profile may contribute to preventing or slowing the progression of PAD in MetS patients. Further interventional studies should be conducted to confirm this association.

Authors' Declaration

- Conflicts of Interest: None.
- We hereby confirm that all the Figures and Tables in the manuscript are ours. Furthermore, any Figures and images, that are not ours, have been included with the necessary permission for republication, which is attached to the manuscript.

- Authors sign on ethical consideration's approval.
- Ethical Clearance: The project was approved by the local ethical committee in University of Djillali LIABES.

Authors' Contribution Statement

S. S., M. A. and M. A. contacted the patients and set up the interviews to collect data, entered the data, developed and analyzed the statistical tests. I. B. and

M. D. Contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

References

1. Ahmed M, Kumari N, Mirgani Z, Saeed A, Ramadan A, Ahmed MH, Almobarak AO. Metabolic syndrome; Definition, Pathogenesis, Elements, and the Effects of medicinal plants on its elements. *J Diabetes MetabDisord.* 2022; 21(1): 1011-1022. <https://doi.org/10.1007/s40200-021-00965-2>.
2. Retterstøl K, Narverud I, Selmer R, Berge KE, Osnes IV, Ulven SM, et al. Severe hypertriglyceridemia in

- Norway: prevalence, clinical and genetic characteristics. *Lipids Health Dis.* 2017; 16(1): 115. <https://doi.org/10.1186/s12944-017-0511-9>.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002; 106(25): 3143-3421 <https://doi.org/10.1161/circ.106.25.3143>.
 4. Dobrowolski P, Prejbisz A, Kuryłowicz A, Baska A, Burchardt P, Chlebus K, et al Metabolic syndrome - a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. *Arch Med Sci.* 2022; 18(5): 1133-1156. <https://doi.org/10.5114/aoms/152921>.
 5. Quillard T, Franck G, Mawson T, Folco E, Libby P. Mechanisms of erosion of atherosclerotic plaques. *Curr Opin Lipidol.* 2017; 28(5): 434-441. <https://doi.org/10.1097/MOL.0000000000000440>.
 6. Sirignano P, Margheritini C, Ruggiero F, Panzano C, Filippi F, Rizzo L, et al. The Ability to Look Beyond: The Treatment of Peripheral Arterial Disease. *J Clin Med.* 2023; 12(9): 3073. <https://doi.org/10.3390/jcm12093073>.
 7. Mohammed A. Correlation between HbA1c and lipid profile in patients with Type 2 diabetes mellitus. *Kirkuk J Med Sci.* 2023; 11(1): 101-107. <https://doi.org/10.32894/kjms.2022.136535.1043>.
 8. Naeem M, Khattak RM, Rehman M ur, Khattak MNK. The role of glycated hemoglobin (HbA1c) and serum lipid profile measurements to detect cardiovascular diseases in type 2 diabetic patients. *SE Asia J Pub Health.* 2016; 5(2):30-34. <https://doi.org/10.3329/SEAJPH.V5I2.28310>.
 9. Annani-Akollor M E, Laing E F, Osei H, Mensah E, Owiredo E W, Afranie B O et al. Prevalence of metabolic syndrome and the comparison of fasting plasma glucose and HbA1c as the glycemic criterion for MetS definition in non-diabetic population in Ghana. *Diabetol Metab Syndr.* 2019; 11: 26. <https://doi.org/10.1186/s13098-019-0423-0>.
 10. Osei K, Rhinesmith S, Gaillard T, Schuster D. Is glycosylated hemoglobinA1c a surrogate for metabolic syndrome in nondiabetic, first degree relatives of African–American patients with type 2 diabetes? *J Clin Endocrinol Metab.* 2003; 88(10): 4596–601. <https://doi.org/10.1210/jc.2003-030686>.
 11. Caverro-Redondo I, Martínez-Vizcaíno V, Álvarez-Bueno C, Agudo-Conde C, Lugones-Sánchez C, García-Ortiz L. Metabolic Syndrome Including Glycated Hemoglobin A1c in Adults: Is It Time to Change? *J Clin Med.* 2019 Dec 1; 8(12): 2090. <https://doi.org/10.3390/jcm8122090>.
 12. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank J K, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *JHypertens.* 2012; 30: 445–448. <https://doi.org/10.1097/HJH.0b013e32834fa8b0>.
 13. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. *Circulation.* 2004; 109(23 Suppl 1): III33-8. <https://doi.org/10.1161/01.CIR.0000131516.65699.ba>.
 14. KDIGO. Chapter 1: Definition and classification of CKD. *Kidney Int Suppl.* 2013; 3: 19–62. <https://doi.org/10.1038/kisup.2012.64>.
 15. Reng RS, Onwuegbuzie GA, Anumah F. Pattern of serum lipid profile of type 2 diabetes patients in a tertiary hospital in Nigeria. *Int J Res Med Sci.* 2021. 25; 9(7): 1854-8. <https://doi.org/10.18203/2320-6012.ijrms20212501>.
 16. Sarkar S, Meshram A. HbA1c and lipid profile levels in the known type 2 diabetic group in the rural region of Vidarbha, Maharashtra, India. *J Evid Based Med Health.* 2017; 4: 1915–1920. <https://doi.org/10.18410/jebmh/2017/374>
 17. Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, et al. Implications of the United kingdom prospective diabetes study. *Diabetes Care.* 2003; 26 Suppl 1: S28-S32. <https://doi.org/10.2337/diacare.26.2007.s28>.
 18. Yost M L. The Current US Prevalence of Peripheral Arterial Disease. *Vasc Dis Manag.* 2023; 20(4): 67-73.
 19. Smolderen KG, Ameli O, Chaisson CE, Heath K, Mena-Hurtado C. Peripheral artery disease screening in the community and 1-year mortality, cardiovascular events, and adverse limb events. *AJPM Focus.* 2022; 1(1): 100016. <https://doi.org/10.1016/j.focus.2022.100016>.
 20. Gninkoun CJ, A Kerekou Hode, AhoudjinouMJ, Padonou GS, Dedjan H, Fanou J. Prevalence and Risk Factors for Peripheral Arterial Disease in Type 2 Diabetic Out Patients in A Care Center in Cotonou. *J Diabetes Complications.* 2021; 5(2); 1-4. <https://doi.org/10.33425/2639-9326.1090>.
 21. Merghit R, AitAthmane M, Lakehal A. Frequency of Peripheral Artery Disease in association with coronary artery disease: a cross-sectional monocentric study in eastern Algeria. *Batna J Med Sci.* 2020; 7(2): 74-8. <https://doi.org/10.48087/BJMSoa.2020.72O2>

22. Vidula H, Liu K, Criqui MH, Szklo M, Allison M, Sibley C, et al. Metabolic syndrome and incident peripheral artery disease - the Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis*. 2015; 243(1): 198-203. <https://doi.org/10.1016/j.atherosclerosis.2015.08.044>.
23. Petra M G, Jobien K O, Yolanda van der G, Ale A, Ton J R, FrankL J Vi. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *Atherosclerosis*. 2004; 173(2): 361-367. <https://doi.org/10.1016/j.atherosclerosis.2003.12.033>.
24. Stoberock K, Kaschwich M, Nicolay SS, Mahmoud N, Heidemann F, Rieß H C, et al. The interrelationship between diabetes mellitus and peripheral arterial disease. *Vasa*. 2021; 50(5): 323-330. <https://doi.org/10.1024/0301-1526/a000925>.
25. Song P, Rudan D, Zhu Y, Fowkes F J I, Rahimi K, Fowkes F G R, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health*. 2019; 7(8): 1020-1030. [https://doi.org/10.1016/S2214-109X\(19\)30255-4](https://doi.org/10.1016/S2214-109X(19)30255-4).
26. Mohammadi K, Woodward M, Hirakawa Y, Zoungas S, Williams B, Lisheng L, et al. Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. *Diabetes Care*. 2016; 39(10):1796-1803. <https://doi.org/10.2337/dc16-0588>.
27. Bougrini Hafida. Dépistage de l'artériopathie oblitérante des membres inférieurs chez les coronariens. These de doctorat. Marrakech, Université Cadi Ayyad Faculté de Médecine et de pharmacie Marrakech, Maroc. 2013.
28. Althouse AD, Abbott JD, Forker AD, Bertolet M, Barinas-Mitchell E, Thurston R, et al. Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. *Diabetes Care*. 2014 ; 37(5) : 1346-1352 <https://doi.org/10.2337/dc13-2303>.
29. NdambweMoussio V, Jemea B, Bayiha J, EpackaEwane M, Ngo Nonga B. Prévalence de l'Artériopathie Oblitérante des Membres Inférieurs chez les Patients Diabétiques à l'Hôpital Général de Douala. *Health Sci Dis*. 2021; 22(4): 29-34.
30. Soyoye DO, Ikem RT, Kolawole BA, Oluwadiya KS, Bolarinwa RA, Adebayo OJ. Prevalence and Correlates of Peripheral Arterial Disease in Nigerians with Type 2 Diabetes. *Adv Med*. 2016: 3529419. <https://doi.org/10.1155/2016/3529419>.
31. Al-Shaheeb S, Hashim HK, Mohammed AK, Al-mashhadani A H, Al-Fandi A. Assessment of lipid profile with HbA1c in type 2 diabetic Iraqi patients. *Revis Bionatura* 2022; 7(3): 29. <https://doi.org/10.21931/RB/2022.07.03.29>.
32. Hussain A, Ali I, Ijaz M, Rahim A. Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. *Ther Adv Endocrinol Metab*. 2017; 8: 51-57. <https://doi.org/10.1177/2042018817692296>.
33. Kundu D, Saikia M, Paul T. Study of the correlation between total lipid profile and glycosylated hemoglobin among the indigenous population of Guwahati. *Int J Life- Sci Sci Res*. 2017; 3 :1175-1180.
34. Alzahrani SH, Baig M, Aashi MM, Al-Shaibi FK, Alqarni DA, Bakhamees WH. Association between glycated hemoglobin (HbA1c) and the lipid profile in patients with type 2 diabetes mellitus at a tertiary care hospital: a retrospective study. *Diabetes Metab Syndr Obes*. 2019; 12: 1639-1644. <https://doi.org/10.2147/DMSO.S222271>
35. Singh G, Kumar A. Relationship among HbA1c and lipid profile in Punjabi type 2 diabetic population. *J Exercise Sci Physiother*. 2011; 7: 99-102.
36. Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. *Vasc Health Risk Manag*. 2019; 15: 149-157. <https://doi.org/10.2147/VHRM.S209830>.

ارتباط الهيموجلوبين السكري ونسبة الدهون مع أمراض اللأوعية الدموية الطرفية في المرضى الذين يعانون من الاضطراب الأيضي من شمال غرب الجزائر

إيمان بورقبة¹، مصطفى ضياف²، سارا سويح³، مليح أسماء³، ملالي أتوية³

¹قسم الأحياء، مختبر الأحياء الدقيقة الجزيئية والبروتيوميات والصحة، كلية العلوم الطبيعية والحياة، جامعة جيلالي ليابس، سيدي بلعباس، الجزائر.
²قسم الأحياء، مختبر التغذية، علم الأمراض، التكنولوجيا الحيوية الزراعية والصحة، كلية العلوم الطبيعية والحياة، جامعة جيلالي ليابس، سيدي بلعباس، الجزائر.
³قسم الأحياء، كلية العلوم الطبيعية والحياة، جامعة جيلالي ليابس، سيدي بلعباس، الجزائر.

الخلاصة

تم إدماج الهيموجلوبين السكري (Hb1Ac) كمؤشر لخلل السكر في الدم بدلا من غلوكوز الدم الصائم (FGB)، لتصنيف المرضى بناء على حوادث الأوعية الدموية، حيث يرتبط Hb1Ac ارتباطا وثيقا بعوامل الأوعية الدموية مثل سرعة موجة النبض وسمك الواسائط الداخلية، نسبة الألبومين / الكرياتينين (ACR) ومع ذلك فإن العلاقة بين Hb1Ac ونسبة الدهون في تطور أمراض الشرايين لا تزال غير مؤكدة. هدفنا الرئيسي من هذه الدراسة هو التحقيق في ارتباط Hb1Ac ونسبة الدهون مع أمراض الأوعية الدموية الطرفية (PAD) في المرضى الذين يعانون من الاضطراب الأيضي (MetS) في شمال غرب الجزائر. أجريت دراستنا المقطعية لمدة ستة أشهر. تم حساب مؤشر كتلة الجسم كالتالي: $BMI (kg/m^2) = weight(kg)/height^2(m^2)$ ، تم استخدام مؤشر الكاحل والعضد (ABI) أقل من 0.9 وتصوير الأوعية لتشخيص PAD وحددنا MetS وفقا لمعايير NECP-ATPIII. تم استعمال اختبار تحليل الارتباط (correlation test) والانحدار الخطي (linear regression) لدراسة الصلة بين Hb1Ac، نسبة السكر في الدم، نسب الدهون وحوادث أمراض الشرايين الطرفية لدى الأفراد المصابين بالاضطراب الأيضي. من بين 300 مصاب بالاضطراب الأيضي، 53% تمثل الذكور. لوحظ وجود ارتباطات إيجابية بين Hb1Ac، FGB، $r=0.753, p<0.001$ و $r=0.288, p<0.001$ وارتباط سلبي مع البروتين الدهني عالي الكثافة (HDL) $r=-0.356, p<0.001$. لم يظهر Hb1Ac أي ارتباط مع الكوليسترول الكلي (TC) والبروتين الدهني منخفض الكثافة (LDL). أظهرت نسب الدهون (LDL/HDL, TC/HDL, TG/HDL) ارتباطات إيجابية مع $Hb1Ac$ $r=0.332, r=0.232, r=0.43$ (أكد اختبار الانحدار الخطي هذه النتائج. أظهر Hb1Ac ارتباطات إيجابية مع FGB و TG في حين أنه يرتبط سلبا بالبروتين الدهني عالي الكثافة (HDL). و مستقل عن البروتين الدهني منخفض الكثافة (LDL) والكوليسترول الكلي (TC) و الجدير بالذكر أن نسب الدهون الثلاثة (LDL/HDL, TC/HDL, TG/HDL) أظهرت ارتباطات إيجابية مع Hb1Ac.

الكلمات المفتاحية: لهيموجلوبين السكري، الدهون، نسب الدهون، الاضطراب الأيضي، مرض الأوعية الدموية الطرفية.